Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 7/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.37 |
| ▸ | FEN1 | P39748 | 5/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | ILK | Q13418 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280993 | 0.91 | ILK (0.38) | DDR1ALOX5APFEN1ILKALPL | |
| SCHEMBL15868285 | 0.84 | DDR1 (0.33) | DDR1ALOX5APFEN1SLC40A1ALDH1A1 | |
| SCHEMBL15426421 | 0.82 | ALDH1A1 (0.42) | ALOX5APFEN1ALDH1A1LMNAHPGD | |
| SCHEMBL15426483 | 0.81 | MPL (0.41) | ALOX5APFEN1ILK | |
| SCHEMBL10281054 | 0.81 | DDR1 (0.39) | DDR1ALOX5APFEN1ALPLALDH1A1 | |
| SCHEMBL11953204 | 0.80 | ALDH1A1 (0.38) | DDR1ALDH1A1LMNAHPGDHTT | |
| SCHEMBL15426428 | 0.80 | ILK (0.35) | DDR1ALOX5APFEN1PTGDR2ILK | |
| SCHEMBL11895033 | 0.79 | DDR1 (0.41) | DDR1ILKALDH1A1LMNAHPGD | |
| SCHEMBL16803714 | 0.78 | DYRK1A (0.39) | ALDH1A1LMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL15426413 | 0.77 | DDR1 (0.41) | DDR1ALOX5APFEN1PTGDR2SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278983-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150148308-A1 | PEST CONTROL COMPOSITION FOR HARMFUL ARTHROPODS, AND PEST CONTROL METHOD FOR HARMFUL ARTHROPODS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-28 | — | — | US | disclosed |
| US-20140364444-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8853238-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20140018373-A1 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018373-A1 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF | NR4A1, NR2C2, NR0B1 | DDR1 3079/4885ALOX5AP 2508/4885FEN1 3336/4885 |
| US-20150148308-A1 | PEST CONTROL COMPOSITION FOR HARMFUL ARTHROPODS, AND PEST CONTROL METHOD FOR HARMFUL ARTHROPODS | SFXN1, OSR1, PIR | DDR1 2720/4885ALOX5AP 4083/4885FEN1 3840/4885 |
| US-20140364444-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | NR4A1, NR2C2, NR0B1 | DDR1 3074/4885ALOX5AP 2391/4885FEN1 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.